While tremendous progress has been made in developing and refining strategies to differentiate hPSCs into clinically suitable insulin‐producing endocrine derivatives or functional β cells,3, 4, 5, 6, 7 clinical application and commercialization of these functional β cells for diabetes treatment are impeded by numerous difficulties, notably the regulatory challenges surrounding the generation, release and clinical use of stem cell‐derived products for cell therapy purposes.8, 9, 10, 11. The gene discussed is INS; the disease is diabetes mellitus.